Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 5/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 4/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 12/20 | 0.74 |
| ▸ | GCGR | P47871 | 12/20 | 0.74 |
| ▸ | MAPK12 | P53778 | 12/20 | 0.74 |
| ▸ | MAPK11 | Q15759 | 12/20 | 0.74 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.74 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.74 |
| ▸ | FRK | P42685 | 2/20 | 0.74 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.74 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.74 |
| ▸ | GSK3B | P49841 | 2/20 | 0.74 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.74 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.74 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.74 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | CIT | O14578 | 1/20 | 0.65 |
| ▸ | GAK | O14976 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17002221 | 0.92 | MAPK14 (0.85) | MAPK14CSNK1DCSNK1EMAPK13GCGR | |
| SCHEMBL18960509 | 0.91 | MAPK14 (0.83) | MAPK14CSNK1DCSNK1EMAPK13GCGR | |
| SCHEMBL17002177 | 0.91 | MAPK14 (0.83) | MAPK14CSNK1DCSNK1EMAPK13GCGR | |
| SCHEMBL17002171 | 0.91 | MAPK14 (0.83) | MAPK14CSNK1DCSNK1EMAPK13GCGR | |
| SCHEMBL17002167 | 0.89 | MAPK14 (0.80) | MAPK14CSNK1DCSNK1EMAPK13GCGR | |
| SCHEMBL17002222 | 0.86 | MAPK14 (0.76) | MAPK14CSNK1DCSNK1EMAPK13GCGR | |
| SCHEMBL17002231 | 0.86 | MAPK14 (0.76) | MAPK14CSNK1DCSNK1EMAPK13GCGR | |
| SCHEMBL19868925 | 0.85 | MAPK11 (1.00) | MAPK14CSNK1DCSNK1EMAPK13GCGR | |
| SCHEMBL15075603 | 0.85 | MAPK11 (1.00) | MAPK14CSNK1DCSNK1EMAPK13GCGR | |
| SCHEMBL30197605 | 0.85 | MAPK14 (1.00) | MAPK14CSNK1DCSNK1EMAPK13GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| EP-4024128-B1 | ELECTRONIC DEVICE AND ACCESSORY | CANON KK (JP) | 2026-05-20 | — | — | EP | claimed |
| EP-4720261-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | University of Southern California (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4134739-B1 | ELECTRONIC DEVICE, AND ACCESSORY | CANON KK (JP) | 2026-02-11 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| EP-4527416-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SystImmune, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| WO-2024243567-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-11-28 | — | — | WO | claimed |
| WO-2024234457-A1 | KIT AND METHOD FOR CONSTRUCTING HEART ORGANOID FROM PLURIPOTENT STEM CELLS | 四川大学华西医院 | 2024-11-21 | — | — | WO | claimed |
| WO-2023222019-A9 | LIGAND-DRUG CONJUGATE AND USE THEREOF | 成都百利多特生物药业有限责任公司 | 2024-11-14 | — | — | WO | claimed |
| WO-2023196235-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-12 | — | — | WO | claimed |
| US-20230310471-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-05 | — | — | US | claimed |
| CN-116758070-A | Method and system for analyzing cells and obtaining morphological characteristics of cells | 深圳安侣医学科技有限公司 | 2023-09-15 | — | — | CN | claimed |
| CN-116656600-A | Kit and method for constructing cardiac organoids by using multifunctional stem cells | 四川大学华西医院 | 2023-08-29 | — | — | CN | claimed |
| CN-111081402-B | Steam generation system suitable for fusion reactor nuclear power station | 核工业西南物理研究院 | 2023-07-14 | — | — | CN | claimed |
| WO-2023060322-A1 | METHODS FOR PRODUCING CARTILAGE AND BONES | MURDOCH CHILDREN'S RESEARCH INSTITUTE (AU) | 2023-04-20 | — | — | WO | claimed |
| CN-111081388-B | Efficient steam generation system suitable for pulse power reactor | 核工业西南物理研究院 | 2022-11-18 | — | — | CN | claimed |
| CN-216647182-U | Use water supply system's switch board | 沈阳华乐世通传动技术有限公司 | 2022-05-31 | — | — | CN | claimed |
| CN-112737294-B | Method for reducing generation of electric heating resistance-inductance load harmonic waves and current impact | 合肥恒力装备有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-111075529-B | Brayton cycle power generation system suitable for pulse type fusion reactor | 核工业西南物理研究院 | 2022-02-18 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | CHEK1, ATR, MRE11 | MAPK14 1503/4885CSNK1D 165/4885CSNK1E 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.